All In MedTech

Device Trial Radar · NCT06825585

Efficacy and Visual Quality of Orthokeratology Lenses With Different Designs

Last checked: Nov 20, 2026Latest source record: Feb 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Jan 1, 2021

Primary completion

Mar 31, 2022

Study completion May 31, 2022

Sponsor

Lead sponsor
Xiaoyan YangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 8 years, up to 13 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Orthokeratology (ortho-k) lens is very effective in slowing down axial elongation in myopic children by 30% to 63% when compared to children wearing single-vision spectacles or contact lenses. More recently, it is reported that the children wearing orthok lens of smaller back optical zone diameter (BOZD) demonstrated a smaller axial elongation when compared to children wearing lens with larger BOZD. We aimed to explored the myopia efficacy and visual quality of ortho-k with different BOZD (5.0mm or 6.2mm).

Conditions

  • Myopia
  • Myopia; Refractive Error

Interventions

  • Orthokeratology with 5.0mm back optical zone diameterDevice

    The orthokeratology lenses used in this study were Double Reservoir Lenses (DRL) manufactured by Precilens (Creteil, France). The lenses feature a dual reverse-curve design with a back optic zone diameter (BOZD) of 5.0 mm.

  • Orthokeratology with a 6.2 mm back optical zone diameterDevice

    The orthokeratology lenses used were Euclid lenses manufactured by Euclid Systems (Herndon, VA, USA). These lenses feature a four-zone, five-curve design with a back optic zone diameter (BOZD) of 6.2 mm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in axial lengthTime frame: The change of baseline and 1years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Eye Hospital Opotometric Center

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.